Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
The company announced that the Food and Drug Administration (FDA) has approved Journavx, a twice-daily pill that it described as a "highly selective NaV1.8 pain signal inhibitor for the treatment of ...
But it's still uncertain whether Vertex's new drug will be the blockbuster the company believes it can be. Vertex Pharmaceuticals ... but none of its addictive safety issues.
The Food and Drug Administration on Thursday approved a new type of nonopioid painkiller from Vertex Pharmaceuticals, NBC ...
Vertex has gained the FDA's approval for its nonaddictive pain med Journavx, which becomes the first significant innovation ...
The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...
Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...
This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of ...
The drug, Journavx by Vertex Pharmaceuticals ... also submitted data from a 250-person study that assessed the drug’s safety and tolerability in patients with pain from surgery, trauma or ...
Vertex Pharmaceuticals Inc. (VRTX) has secured FDA approval for Suzetrigine, an oral, non-opioid, highly selective NaV1.8 pain signal ...
(RTTNews) - Vertex Pharmaceuticals Inc. (VRTX ... for the treatment of adults with moderate-to-severe acute pain. The drug, which will be marketed under the brand name JOURNAVX, is the first ...